Kymera Therapeutics - Clinical Study Data for KT-621 Creates Excitement!
Reading Time: 1 minute
Business Drivers: At Kymera Therapeutics (KYM ) is a biopharmaceutical company focused on developing innovative drugs using what is known as "Targeted Protein Degradation" (TPD). The aim is to target previously untreatable or inadequately addressed targets, particularly transcription factors like STAT6 or IRF5. The company concentrates on new therapeutic approaches for the treatment of inflammatory diseases such as atopic dermatitis or asthma. On December 9, Kymera Therapeutics published positive data from a Phase 1b study on its oral...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
